Definition
Osteosarcoma is a primary malignant bone tumor that produces immature bone (osteoid) or bone matrix through malignant mesenchymal cells. It is the most common primary bone cancer in children and adolescents, usually developing in the metaphyseal area of long bones, particularly in the distal femur, proximal tibia, and proximal humerus.
Description
- Osteosarcoma is a malignant tumor that originates in bone-forming tissue, characterized by cancerous mesenchymal cells that directly produce osteoid or immature bone
- Common sites include the long bones of the limbs, particularly around the knee (distal femur, proximal tibia) and the proximal humerus
- Metastasis mainly occurs in the lungs and other bones
Classification of Osteosarcoma
- Conventional (High-Grade) Osteosarcoma
- Most common type, accounting for approximately 75%
- Subtypes are categorized according to the predominant tumor matrix: osteoblastic (osteoid), chondroblastic (cartilaginous), and fibroblastic (fibrous, spindle-cell)
- Small Cell Osteosarcoma
- Histologically similar to Ewing sarcoma, but it exhibits osteoid production
- Surface osteosarcomas originate from the bone surface rather than the medullary cavity.
- Parosteal osteosarcoma (low grade) typically occurs in the posterior distal femur and tends to grow slowly
- Periosteal osteosarcoma (intermediate grade) – located on the diaphysis, featuring a cartilaginous matrix and surface-based growth
- High-grade surface osteosarcoma is a rare and aggressive tumor that occurs on the surface
- Secondary Osteosarcoma
- This condition commonly occurs in older adults and is often associated with Paget’s disease of bone or prior radiation exposure
- Telangiectatic Osteosarcoma
- Uncommon, aggressive subtype
- Features blood-filled spaces similar to aneurysmal bone cysts, but with malignant osteoid production
Epidemiology
Incidence/Prevalence
- Approximately 800 to 1,000 new cases of osteosarcoma are diagnosed annually in the United States
- Prevalence: Osteosarcoma is uncommon; its overall prevalence in the U.S. remains low due to variable survival rates and its frequent occurrence in adolescents and young adults.
Age
- First peak occurs in adolescents and young adults aged 10–20, especially during growth spurts
- Second, smaller peak: Adults over 60, commonly linked to Paget’s disease of bone or radiation-induced osteosarcoma
- Median age at diagnosis is approximately 18 years
Gender
- Most U.S. reports indicate a male-to-female ratio of approximately 1.2–1.5:1
- Boys and young men are more commonly affected, particularly during adolescence
Race
- Adolescents of African American and Hispanic backgrounds face a marginally increased risk compared to non-Hispanic Whites
- The Asian/Pacific Islander populations have the lowest incidence
Risk factors
- General
- Demographic & Growth-Related:
- Age: Adolescents (10–20 years) during growth spurts
- Sex: Slight male predominance
- Height: Tall stature in teenagers
- Genetic Syndromes:
- Hereditary retinoblastoma (RB1 mutation)
- Li-Fraumeni syndrome (TP53 mutation)
- Rothmund-Thomson syndrome
- Bloom syndrome
- Werner syndrome
- Bone Disorders:
- Paget’s disease of the bone (especially in older adults)
- Fibrous dysplasia
- McCune-Albright syndrome
- Environmental & Iatrogenic:
- Prior radiation therapy (especially high-dose exposure)
- Alkylating chemotherapy (e.g., cyclophosphamide)
- Chronic bone injury or inflammation (rare, debated)
- Physiological
- Rapid Bone Growth:
- Adolescents during growth spurts (ages 10–20)
- Tall stature is associated with higher mitotic activity in growth plates
- Hormonal Influences:
- Increased growth hormone and IGF-1 levels during puberty
- Possible role of sex steroids in modulating osteoblast proliferation
- Bone Remodeling Stress:
- Chronic microtrauma or repetitive stress (e.g., athletic overuse)
- Increased osteoblastic activity in active growth zones
- Metabolic & Cellular Factors:
- Increased osteoblast activity and cell division rate
- Dysregulation of the TP53 and RB1 pathways affecting cell cycle control
- Immunologic & Inflammatory Signals:
- Local cytokine release (e.g., IL-6, TNF-α) may promote the tumor microenvironment
- Chronic inflammation or previous bone injury (rare, debated)
Etiology
- Genetic Predisposition:
- RB1 mutation leads to hereditary retinoblastoma
- TP53 mutation leads to Li-Fraumeni syndrome
- Other syndromes: Rothmund-Thomson, Bloom, Werner
- Environmental & Iatrogenic Factors:
- Prior radiation exposure (especially high-dose, pediatric)
- Alkylating chemotherapy (e.g., cyclophosphamide)
- Chronic bone disorders (e.g., Paget’s disease, fibrous dysplasia)
- Growth-Related Risk:
- Adolescents During Rapid Growth (10–20 Years)
- Tall stature and heightened osteoblastic activity
- Pathophysiology
- Origin:
- Malignant transformation of primitive mesenchymal cells
- Arises in the metaphysis of long bones (e.g., distal femur, proximal tibia)
- Cellular Features:
- High-grade spindle cells producing malignant osteoid
- Frequent mitoses, nuclear atypia, and necrosis
- Molecular Pathways:
- RB1 and TP53 inactivation result in the loss of cell cycle control
- MDM2 amplification leads to p53 suppression
- Wnt/β-catenin and IGF-1 signaling lead to increased proliferation
- Tumor Behavior:
- Aggressive invasion into the cortex and soft tissue
- Hematogenous spread → lungs are the most common site
- Rare lymphatic spread
- Histologic Subtypes:
- Conventional (osteoblastic, chondroblastic, fibroblastic)
- Telangiectatic (blood-filled spaces that mimic aneurysmal bone cysts)
- Small cell, parosteal, periosteal, high-grade surface
History
- Chief Complaint
- Patients typically experience localised bone pain, commonly around the knee or upper arm
- Pain might intensify at night and may not be alleviated by rest
- Some patients notice a palpable lump or swelling at the affected site.
- History of Present Illness (HPI)
- Pain lasts for weeks to months and worsens gradually
- Swelling/mass: Firm and tender, gradually enlarging
- Functional limitations include difficulty walking, limping, or a reduced range of motion near the affected joint
- Pathologic fracture: Sometimes the initial sign
- Medical and surgical history of the patient
- History of radiation therapy is a risk factor for secondary osteosarcoma
- Paget’s disease of the bone in older adults
- History of fractures or orthopaedic surgeries at the site, which can sometimes be misdiagnosed before tumor confirmation
- Family and Social History
- Family history of hereditary conditions such as retinoblastoma, Li-Fraumeni syndrome, or Rothmund-Thomson syndrome (indicating genetic predisposition)
- Rare family cancer syndromes
- Social history is usually not contributory, although smoking and alcohol are not directly linked
- Adolescents engaged in active sports may delay reporting pain, believing it is just a sports injury
Physical findings on examination
- Local Findings:
- A firm, immobile mass over the long bone, often in the metaphyseal region.
- Tenderness on palpation
- Warmth or erythema (if aggressive or inflamed)
- Decreased range of motion near the joint
- Limb asymmetry or deformity
- Signs of a pathologic fracture (crepitus, instability)
- Neurovascular Assessment:
- Distal pulses intact or diminished (compression risk)
- Sensory deficits or paresthesia (nerve involvement)
- Motor weakness if the neurovascular bundle is affected
- Systemic Signs:
- Fever (if caused by infection or tumor necrosis)
- Weight loss and fatigue (advanced disease)
- Lymphadenopathy (rare; consider metastasis or alternative diagnosis)
- Pulmonary Signs (if metastatic):
- Decreased breath sounds
- Cough, dyspnea
- Rales or dullness indicating pleural involvement
General treatment items
- Neoadjuvant Chemotherapy:
- MAP regimen: Methotrexate (HDMTX), Doxorubicin, Cisplatin
- Goal: Tumor reduction and control of micrometastases
- Surgical Resection:
- Performed after neoadjuvant response assessment
- Limb-sparing is preferred if margins can be achieved
- Adjuvant Chemotherapy:
- Same MAP agents after resection
- Duration: Normally 6–12 months overall
- Surveillance:
- Chest CT and local MRI every 3–6 months for 2 years
- Annual imaging thereafter
Surgical Interventions
- Limb-Sparing Surgery:
- Wide excision with endoprosthetic or allograft reconstruction
- Preferred in cases of extremity tumors with neurovascular preservation
- Amputation:
- Indicate if margins are not achievable or if there is neurovascular compromise
- Types: above-knee, below-knee, forequarter, etc
- Rotationplasty:
- Functional alternative for pediatric patients
- Preserves limb function through ankle-as-knee reconstruction
- Metastasectomy:
- Pulmonary nodule resection (if isolated and resectable)
- Enhances survival in certain cases
Adjunctive Therapies
- Radiation Therapy:
- Rarely used; reserved for unresectable tumors or palliation.
- May be considered in extraskeletal or axial lesions
- Targeted Therapy & Trials:
- Investigational: Sorafenib and immune checkpoint inhibitors
- Supportive Care:
- Anti-emetics, hydration, and nutritional support
- Physical therapy and prosthesis fitting
- Psychosocial counselling and survivorship planning
Medications indicated with specific doses
Toxoids
Immunoglobulins
Vasodilators
Thrombolytic agents
Dietary or Activity restrictions
- During Chemotherapy:
- Neutropenic precautions: avoid raw meats, unpasteurized dairy, and unwashed fruits and vegetables
- Hydration: at least 2L per day unless contraindicated
- Limit high-sodium and processed foods for renal protection
- Avoid alcohol (hepatotoxicity, drug interactions)
- Eating small, frequent meals to manage nausea and mucositis
- Post-Surgery or During Recovery:
- High-protein, high-calorie diet for wound healing
- Calcium and vitamin D supplementation (if bone resection occurs)
- Monitor for gastrointestinal side effects (e.g., constipation from opioids)
- During Active Disease or Chemotherapy:
- Avoid contact sports or high-impact activities to reduce fracture risk
- Avoid strenuous exertion during neutropenia or fatigue
- Use assistive devices if experiencing limb weakness or post-op instability
- Postoperative Recovery:
- No weight-bearing on affected limb until cleared by orthopedist or physical therapist
- Gradual return to activity through physical therapy
- Avoid swimming until surgical wounds are completely healed
- Long-Term:
- Promote low-impact aerobic exercises like walking and cycling
- Monitor for prosthesis wear or limb dysfunction
- Psychosocial support for reintegration into school or work
Disposition
Admission Criteria
- Diagnostic Confirmation:
- Radiologic evidence of an aggressive bone lesion (MRI, CT, X-ray)
- Suspicion or confirmation through biopsy (core needle or open)
- Clinical Indications for Admission:
- Severe localized pain or swelling that impairs function
- Pathologic fracture needing orthopedic stabilization
- Neurovascular compromise (such as limb ischemia or nerve compression)
- Rapid tumor growth or soft tissue infiltration
- Suspected or confirmed pulmonary metastases (e.g., cough, dyspnea)
- Fever, neutropenia, or infection during chemotherapy
- Chemotherapy initiation or inpatient cycle (MAP regimen)
- Preoperative assessment for limb-sparing surgery or amputation
- Postoperative care (pain management, wound monitoring, rehabilitation)
Discharge criteria
- Clinical Stability:
- Pain managed with oral analgesics
- Afebrile for at least 24 hours
- Hemodynamically stable
- No signs of active infection or neutropenic fever
- Postoperative Recovery (if applicable):
- Wound healing satisfactory or manageable; patient is an outpatient.
- Mobility restored or physical therapy started
- Prosthesis fitted or limb-sparing function is adequate
- Treatment Completion or Transition:
- Chemotherapy cycle completed or transitioned to outpatient infusion
- Imaging reviewed, and no urgent surgical or oncologic intervention is necessary.
- Multidisciplinary plan established (oncology, ortho, PT, social work)
- Patient & Family Preparedness:
- Education on recognizing signs of recurrence or complications (pain, swelling, cough)
- Follow-up appointments scheduled (oncology, imaging, labs)
- Arranged home care, transportation, and psychosocial support